Study Number		AEWS1221			
NCT #		NCT02306161			
Dataset #		NCT02306161-D1			
PMID #		36669140			
Data can manuscri	be used to approxi pts may not be pos	mate publish ssible in som	ta or not applicable for analyses. ned study findings, but exact reproduction of e cases (e.g., when data must be modified to ne further data cleaning).		
Variable Number	Variable Name	Туре	Label	Notes	
1	USI_PatientID	character	Patient ID		
2	CONSORTA	character	Enrolled and randomized		
3	CONSORTB	character	Randomized assignment	Corresponds to variable <i>Treatment</i> in the D2, D4, and D5 data submissions	
4	CONSORTC	character	Ineligible		
5	CONSORTD	character	Ineligible: Reason		
6	CONSORTE	character	Eligible and randomized		
7	CONSORTF	character	Off protocol		
8	CONSORTG	character	Off protocol reason		
9	CONSORTH	character	Completion of protocol therapy		
10	age	numeric	Age (years)		
11	sex	character	Sex		
12	race	character	Race		
13	sitecat1	character	Primary tumor site location group		
14	sitecat2	character	Primary tumor site tissue type		
15	sitecat3	character	Primary tumor site skeletal group		
16	sitecat4	character	Primary Site (include soft tissue)		
17	strat_el_str	character	Stratum, pre-specified strata		
18	agestratum	character	Age at enrollment (years)		
19	lungstratum	character	Lung metastatic pattern at enrollment		
20	metscat1	character	Metastatic pattern (Sites of metastatic disease)		
21	lctyperv	character	Local control type reviewed		

Study Number		AEWS122	AEWS1221			
NCT #		NCT02300	NCT02306161			
Dataset #		NCT0230	NCT02306161-D1			
PMID #		36669140	36669140			
Data c manus	an be used to appr cripts may not be	oximate publis possible in sor	lata or not applicable for analyses. shed study findings, but exact reproduction of ne cases (e.g., when data must be modified for one further data cleaning).	1		
22	gllctyperv	character	Local control type reviewed group			
23	time1	numeric	Induction Time (days)	Time on induction therapy		
24	time2	numeric	Consolidation Time (days)	Time on consolidation therapy		
25	time3	numeric	Induction & Consolidation Time (days)	Time on induction and consolidation therapy		
26	first_cleared	character	Reporting Period Bone Marrow (BM) First Cleared			
27	suvsite	numeric	Maximum SUV by PET of the primary tumor at initial diagnosis and prior to initiation of protocol therapy			
28	suvmsrmt	numeric	Maximum SUV by FDG-PET of the primary tumor site			
29	suvratio	numeric	SUV ratio Induction: Baseline Maximum SUV by FDG-PET primary tumor site			
30	efstype	numeric	EFS event: 1 = any first progression, 2 = SMN, 3 = Death, 0 = censored			
31	efstype1	numeric	EFS event progression at: 1 = primary, 2 = metastatic, 3 = combined site, 4 = SMN, 5 = Death, 0 = censored			
32	time_efs	numeric	Event free survival time (days)			
33	ostype	numeric	OS event: $1 = Death, 0 = censored$			
34	time_os	numeric	Overall survival time (days)			